...
首页> 外文期刊>BJU international >Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody cG250.
【24h】

Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody cG250.

机译:酪氨酸激酶抑制剂治疗肾细胞癌对碳酸酐酶IX特异性嵌合单克隆抗体cG250积累的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To investigate the effect of three different tyrosine kinase inhibitors (TKIs) on the biodistribution of chimeric monoclonal antibody (mAb) cG250, which identifies carbonic anhydrase IX (CAIX), in nude mice bearing human renal cell carcinoma (RCC) xenografts. TKIs represent the best, but still suboptimal treatment for metastatic RCC (mRCC) and combined therapy or sequential therapy might be beneficial. CAIX is abundantly over expressed in RCC and clinical trials have shown abundant and specific tumour accumulation of cG250. Combining a TKI with mAb cG250, involved in a different effector mechanism, might lead to improved tumour responses and survival in patients with mRCC. MATERIALS AND METHODS: Nude mice bearing human RCC xenografts were treated orally with 0.75 mg/day sunitinib, 1 mg/day vandetanib, 1 mg/day sorafenib or vehicle control for 7 or 14 days. At 7 days, mice were injected i.v. with 185 kBq/5 microg (125) I-cG250. Mice were killed at predetermined days and cG250 biodistribution was determined. Tumours were analysed by immunohistochemistry for the presence of endothelial cells, laminin, smooth muscle actin, CAIX expression and uptake of mAb cG250. RESULTS: While on TKI treatment, tumour uptake of cG250 decreased dramatically, tumour growth was slightly inhibited and vascular density decreased considerably as judged by various markers. When treatment was stopped at 7 days, there was robust neovascularization, mainly at the tumour periphery. Consequently, cG250 uptake also recovered, albeit cG250 uptake appeared to be restricted to the tumour periphery where vigorous neovascularization was visible. CONCLUSIONS: Simultaneous administration of a TKI and mAb cG250 severely compromised mAb accumulation. However, shortly after discontinuation of TKI treatment mAb accumulation was restored. Combined treatment strategies with TKI and mAb should be carefully designed.
机译:目的:研究三种不同的酪氨酸激酶抑制剂(TKIs)对带有人肾细胞癌(RCC)异种移植物的嵌合单克隆抗体(mAb)cG250生物识别碳酸酐酶IX(CAIX)的影响。 TKIs是转移性RCC(mRCC)的最佳治疗方法,但仍不是最佳治疗方法,联合治疗或序贯治疗可能是有益的。 CAIX在RCC中大量过量表达,临床试验表明cG250有大量特异性肿瘤积累。将TKI与mAb cG250结合在一起,参与不同的效应器机制,可能会改善mRCC患者的肿瘤反应和生存率。材料与方法:将携带人RCC异种移植物的裸鼠口服0.75 mg /天舒尼替尼,1 mg /天vandetanib,1 mg /天索拉非尼或赋形剂对照治疗7或14天。在第7天,经静脉注射小鼠。含185 kBq / 5 microg(125)I-cG250。在预定的天数处死小鼠并测定cG250的生物分布。通过免疫组织化学分析肿瘤中内皮细胞,层粘连蛋白,平滑肌肌动蛋白,CAIX表达和mAb cG250摄取的存在。结果:在TKI治疗期间,通过各种标志物判断,肿瘤对cG250的摄取显着下降,肿瘤的生长受到轻微抑制,血管密度显着下降。当在第7天停止治疗时,主要在肿瘤外围有明显的新生血管形成。因此,cG250的摄取也恢复了,尽管cG250的摄取似乎仅限于可见新血管形成的肿瘤周围。结论:同时施用TKI和mAb cG250严重损害了mAb的积累。但是,在停止TKI治疗后不久,mAb的积累得以恢复。应仔细设计与TKI和mAb结合的治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号